VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO GI 2022 | Investigating fruquintinib in patients with refractory metastatic CRC

Arvind Dasari, MD, MS, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the Phase I trial investigating the preliminary efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer (mCRC) in the US. Fruquintinib is a potent and highly selective VEGFR 1, 2, 3 tyrosine kinase inhibitor (TKI). Following the Phase III FRESCO (NCT02314819) clinical trial, fruquintinib was approved in China for patients with refractory metastatic rectal cancer. In the new Phase I trial for patients with refractory mCRC, two cohorts of patients are being investigated. Cohort b includes patients who have progressed on all standard of care (SOC) therapies, including TAS1 or 2 and regorafenib. In cohort c, patients had progressed on all prior therapies but must not have received TAS1 or 2 or regorafenib. There were 40 patients in each cohort. In both cohorts, patients received fruquintinib daily, 3 weeks on and 1 week off across a 28 day cycle. The results showed a good disease control rate with 68% in cohort b and 58% in cohort c. The progression-free survival (PFS) rate was approximately 4.7 months in cohort b and 3.7 months in cohort c and overall survival (OS) was 11 months in cohort b and 9 months in cohort c. Based on these results the global, placebo controlled, Phase III FRESCO-2 (NCT04322539) trial was launched assessing fruquintinib plus best supportive care compared to best supportive care alone in patients with refractory mCRC. This interview took place at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2022.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter